PLEASANTON, Calif., Aug. 29, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10.
Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 12:55 p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).
A webcast of the presentation will be available at http://cc.talkpoint.com/morg007/090814a_ac/?entity=125_7H161FR, or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate II® LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures the CentriMag® and PediMag®/PediVAS® product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and HeartMate III, HeartMate PHP, PVAD, IVAD and Pocket Controller are trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.
|SOURCE Thoratec Corporation|
Copyright©2014 PR Newswire.
All rights reserved